Youneng J. Wei
Chengdu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.
Journal: Lancet (London, England)
Published: April 22, 2026
Baseline Nutritional Indices as Prognostic Indicators in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma Treated with the PD-L1 Inhibitor KL-A167: A Secondary Analysis of the KL-A167 Trial.
Journal: Cancer management and research
Published: March 30, 2026
Association of basal thyroid function with clinical outcomes in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-L1 inhibitor KL-A167: a multicenter post hoc analysis.
Journal: Endocrine connections
Published: January 29, 2026
Energy-Dependent Shifts of Medium-Scale Anisotropies in Very-High-Energy Cosmic Rays Observed by LHAASO-KM2A.
Journal: Physical review letters
Published: December 18, 2025
Transient Large-Scale Anisotropy in TeV Cosmic Rays due to an Interplanetary Coronal Mass Ejection.
Journal: Physical review letters
Published: November 17, 2025
CaSR Activation Triggers Mandibular Overgrowth in Familial Mandibular Prognathism Patients and Mice.
CaSR Activation Triggers Mandibular Overgrowth in Familial Mandibular Prognathism Patients and Mice.
Journal: Journal of dental research
Published: November 04, 2025
Precise Measurement of the Cosmic Ray Helium Spectrum above 0.1 PeV.
Journal: Physical review letters
Published: November 03, 2025
Evidence of Cosmic-Ray Acceleration up to Sub-PeV Energies in the Supernova Remnant IC 443.
Journal: Physical review letters
Published: October 30, 2025
First Detection of Ultrahigh Energy Emission from Gamma-Ray Binary LS I +61° 303.
Journal: Physical review letters
Published: October 24, 2025
Correction: Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors.
Journal: Cancer immunology, immunotherapy : CII
Published: September 29, 2025
Correction: Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167).
Journal: Cancer immunology, immunotherapy : CII
Published: September 29, 2025
Prognostic Impact of Advanced Lung Cancer Inflammation Index (ALI) on Immunotherapy Outcomes in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter Post Hoc Analysis.
Journal: Journal of inflammation research
Published: June 15, 2025
Last Updated: 09/26/2026